


Applicant : Lipton
Serial No. : 08/346,910
Filed : November 30, 1994
Page : 2

Attorney's Docket No.: 08262-017004



encode a peptide that promotes the regeneration of a process of a central or peripheral neuron in vitro. The rejection is based on the finding that the specification does not adequately describe, give examples, or provide guidance on purification of fragments that would encode such functional peptide fragments.

In contrast, the office action concludes that claims to the deposited clones (claims 8 and 11-12) are in condition for allowance because, although the deposited clones are only partial sequences, they meet the utility and written description guidelines because they have been described as capable of being used to isolate the full length sequence of what is now known as human MEF2C, which the specification correctly describes as being useful for promoting process generation of neurons.

Accordingly, claim 13 has been canceled.


New claim 14 does not imply any function, other than use to isolate the full length sequence of what is now known as human MEF2C. Basis for claim 14 is found at page 4, lines 13-20 describing nucleic acid probes of at least 15-20 contiguous bases.

For the reasons stated above, Applicant submits that all of the claims are now in condition for allowance, and requests a prompt notice to that effect. Please apply any charges not covered or any credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

8/24/00


John W. Freeman, Esq.
Reg. No. 29,066

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906